会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • INTRALYMPHATIC CHEMOTHERAPY DRUG CARRIERS
    • INTRALYMPHATIC化疗药物载体
    • WO2009097570A3
    • 2009-11-12
    • PCT/US2009032713
    • 2009-01-30
    • UNIV KANSASFORREST LAIRDCOHEN MARKCAI SHUANG
    • FORREST LAIRDCOHEN MARKCAI SHUANG
    • A61K47/48A61K9/08A61K33/24A61K47/30A61P35/00
    • A61K45/06A61K9/0019A61K38/21A61K47/61
    • A chemotherapeutic composition can be configured for subcutaneous administration for preferential intralymphatic accumulation while also providing a therapeutic systemic concentration that is not toxic. The composition can include a pharmaceutically acceptable carrier, and a nanoconjugate configured for preferential intralymphatic accumulation after subcutaneous administration. The nanoconjugate can include a nanocarrier configured for preferential intralymphatic accumulation after subcutaneous or interstitial administration, and a plurality of chemotherapeutic agents coupled to the nanocarrier. The nanoconjugate can have a dimension of about 10 nm to about 50 nm. Also, the nanoconjugate can be loaded with the chemotherapeutic agents from about 10% to about 50% w/w. The nanocarrier can be a hyaluronan polymer of about 3 kDa to about 50 kDa. Alternatively, the nanocarrier can be a dendrimer.
    • 化疗组合物可被配置用于皮下给药以优先淋巴内积聚,同时还提供无毒的治疗性全身浓度。 该组合物可以包括药学上可接受的载体和配置用于皮下给药后优先淋巴内积聚的纳米缀合物。 纳米缀合物可以包括纳米载体和多种与​​纳米载体偶联的化疗剂,所述纳米载体被配置用于皮下或间质给药后的优先淋巴内积聚。 纳米缀合物可具有约10nm至约50nm的尺寸。 而且,纳米缀合物可以加载约10%至约50%w / w的化学治疗剂。 纳米载体可以是约3kDa至约50kDa的透明质酸聚合物。 或者,纳米载体可以是树状聚合物。